Acorda Therapeutics Inc  

(Public, NASDAQ:ACOR)   Watch this stock  
Find more results for ACOR
21.40
+0.20 (0.94%)
After Hours: 21.40 0.00 (0.00%)
Dec 9, 4:30PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 20.98 - 22.15
52 week 16.40 - 43.63
Open 21.25
Vol / Avg. 368,712.00/616,626.00
Mkt cap 1.02B
P/E     -
Div/yield     -
EPS -0.49
Shares 46.11M
Beta 1.55
Inst. own 106%
Feb 9, 2017
Q4 2016 Acorda Therapeutics Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Nov 29, 2016
Acorda Therapeutics Inc at Piper Jaffray Healthcare Conference - Webcast
Nov 16, 2016
Acorda Therapeutics Inc at Stifel Healthcare Conference - Webcast
Oct 27, 2016
Q3 2016 Acorda Therapeutics Inc Earnings Release
Oct 27, 2016
Q3 2016 Acorda Therapeutics Inc Earnings Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '16) 2015
Net profit margin -9.61% 2.24%
Operating margin -4.04% 6.90%
EBITD margin - 9.95%
Return on average assets -3.92% 1.02%
Return on average equity -7.63% 1.93%
Employees 535 -
CDP Score - -

Address

420 Saw Mill River Rd
ARDSLEY, NY 10502-2605
United States - Map
+1-914-3474300 (Phone)
+1-914-3474560 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Acorda Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in the identification, development and commercialization of therapies that restore function and recovers the lives of people with neurological disorders. Its commercial products include Ampyra, Fampyra, Zanaflex Capsules and a generic version of the capsules, Zanaflex tablets and Qutenza. Its research and development programs include CVT-301, Dalfampridine, Plumiaz, Neuregulin Program, Remyelinating Antibodies Program, CVT-427 and Chondroitinase Program. Its Ampyra is an oral drug for the treatment to improve walking in patients with multiple sclerosis. Zanaflex Capsules and tablets are used as short-acting drugs for the management of spasticity. Qutenza is a dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia. Its pipeline of neurological therapies addresses a range of disorders, including Parkinson's disease, chronic post-stroke walking deficits and migraine.

Officers and directors

Ron Cohen M.D. President,Chief Executive Officer, Director
Age: 60
Bio & Compensation  - Reuters
David Lawrence Chief Business Operations, Principal Accounting Officer
Age: 59
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Andrew R. Blight Ph.D. Chief Scientific Officer
Age: 64
Bio & Compensation  - Reuters
Jane Wasman J.D. President - International, General Counsel, Corporate Secretary
Age: 60
Bio & Compensation  - Reuters
Burkhard Blank M.D. Chief Medical Officer
Age: 60
Bio & Compensation  - Reuters
Andrew Hindman Chief Business Development Officer
Age: 44
Bio & Compensation  - Reuters
Lauren M. Sabella Chief Commercial Officer
Age: 54
Bio & Compensation  - Reuters
Barry E. Greene Independent Director
Age: 52
Bio & Compensation  - Reuters
Peder K. Jensen M.D. Independent Director
Age: 61
Bio & Compensation  - Reuters
John P. Kelley Independent Director
Age: 62
Bio & Compensation  - Reuters